COO Stock Surges 22% in Past Three Months: What's Driving the Uptrend?

• COO posted its 10th consecutive quarter of beating expectations with Q2 revenues reaching $1.08 billion and adjusted EPS of $1.21, up 26% year-over-year
• MiSight myopia-control product revenue jumped 24% to $32 million, while CooperSurgical's fertility business grew 10% organically to $144 million
• Asia-Pacific revenues declined 6% with weakness in Japan and China expected to persist through 2027, while forex headwinds, tariffs and freight costs are pressuring gross margins

Summary: Cooper Companies (COO) Stock Rally Analysis

Key Performance Metrics:

Cooper Companies' stock has surged 22.2% over the past three months, significantly outperforming the S&P 500's 4.6% gain. In Q2, the company delivered its 10th consecutive earnings beat with revenues rising 8% to a record $1.08 billion and adjusted EPS climbing 26% to $1.21.

Main Business Segments:

*CooperVision* (contact lenses) demonstrated market-leading growth through its premium silicone hydrogel products. The MiSight myopia-control product line grew 24% to $32 million, with strong adoption in Japan and Europe. Biofinity lenses grew 5% organically, supported by toric and multifocal variants.

*CooperSurgical* posted 8% revenue growth (6% organic), with the fertility division expanding 10% organically to $144 million, driven by capital equipment, genomics, and new clinic wins.

Market Challenges:

The company faces headwinds in Asia-Pacific, where CooperVision revenues declined 6% due to weakness in Japan and China. Legacy hydrogel rationalization is expected to pressure results through 2027. Management anticipates forex volatility, tariffs, and freight costs will compress Q3 gross margins.

Strategic Developments:

Cooper Companies is conducting a strategic review of CooperSurgical after receiving "significant indications of interest," which could reshape its portfolio structure.

Competitive Landscape:

Key competitors include Alcon (ALC), which reported 7% Vision Care growth with contact lens sales up 5% to $726 million, Bausch + Lomb (BLCO), and Baxter (BAX) in surgical markets.

Outlook:

While near-term margin pressures and Asia-Pacific weakness present risks, sustained innovation in premium contact lenses and fertility market recovery support continued growth potential.